The problem of renal function monitoring in patients treated with the novel antiretroviral drugs

HIV Clinical Trials

Volumn 15, Issue 3, 2014, Pages 87-91

  Maggi, Paolo ^a,j   Montinaro, Vincenzo ^a   Rusconi, Stefano ^b   Di Biagio, Antonio ^c   Bellagamba, Rita ^d   Bonfanti, Paolo ^e   Calza, Leonardo ^f   Corsi, Paola ^g   Montella, Francesco ^h   Mussini, Cristina ⁱ  

^a POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e Hospital A Manzoni   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g CAREGGI UNIVERSITY HOSPITAL   (Italy)

^h Hospital San Giovanni   (Italy)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^j UNIVERSITY OF BARI   (Italy)

more..

Author keywords

cobicistat; dolutegravir; HIV; kidney; rilpivirine

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COBICISTAT; CREATININE; DOLUTEGRAVIR; NEW DRUG; PHOSPHATE; RILPIVIRINE; URIC ACID;

ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; KIDNEY TUBULE EXCRETION; KIDNEY TUBULE FUNCTION; NEPHROTOXICITY; PATIENT MONITORING; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; URINARY EXCRETION;

COBICISTAT; DOLUTEGRAVIR; HIV; KIDNEY; RILPIVIRINE;

ANTI-RETROVIRAL AGENTS; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; MONITORING, PHYSIOLOGIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84903143640     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1503-87     Document Type: Article

References (32)

1. Maggi P, Bartolozzi D, Bonfanti P, et al. Renal complications in HIV disease: Between present and future. AIDS Rev. 2012;14:37-53.
2. Ryom L, Mocroft A, Kirk O, et al. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS. 2014;28(2):187-199.
3. Margolick JB, Jacobson L P, Schwartz GJ, et al. Factors affecting glomerular fi ltration rate, as measured by iohexol disappearance, in men with or at risk for HIV infection. PLoS One. 2014;9(2):e86311.
4. Danjuma MI, Mohamad-Fadzillah NH, Khoo S. An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: An examination of a large population database (MHRA database). Int J STD AIDS. 2014;25(4):273-279.
5. Maggi P, Montinaro V, Bellacosa C, et al. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir. AIDS Patient Care STDS. 2012;26(1):5-11.
6. Flandre P, Pugliese P, Cuzin L, et al; New AIDS Data Group. Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol. 2011;6(7):1700-1707.
7. Molina JM, Cahn P, Grinsztejn B, et al; ECHO Study Group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238-246.
8. Cohen CJ, Andrade-Villanueva J, Clotet B, et al; THRIVE Study Group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial. Lancet. 2011;378(9787):229-237.
9. Cohen CJ, Molina JM, Cassetti I, et al; ECHO, THRIVE Study Groups. Week 96 effi cacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS. 2013;27(6):939-950.
10. Urakami Y, Kimura N, Okuda M, Inui K. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res. 2004;21(6):976-981.
11. Gagneux-Brunon A, Mariat C, Delanaye P. Cystatin C in HIV-infected patients: Promising but not yet ready for prime time. Nephrol Dial Transplant. 2012;27(4):1305-1313.
12. Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles ofdrug transporters and metabolizing enzymes in the disposition and druginteractions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41(2):353-361.
13. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolute-gravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735-774.
14. Koteff J, Borland J, Chen S et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2012;75:990-996.
15. Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir (DTG; S/GSK1349572) in combination therapy exhibits rapid and sustained antiviral response in antiretroviral-naïve adults: 96-week results from SPRING-1 (ING112276). Presented at: 19th CROI; March 5-8, 2012. Abstract K-102.
16. Mathias AA, German P, Murray B P, et al. Pharmacokinetics and pharmacodynamics of GS-9350: A novel pharmaco-kinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010;87(3):322-329
17. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, et al. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: Functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010;298(4):F997-F1005.
18. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3, 418 individuals with CKD. Am J Kidney Dis. 2008;51:395-406.
19. Jaroszewicz J, Wiercinska-Drapalo A, Lapinski TW, et al. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration. Antivir Ther. 2006;11:641-645.
20. Longenecker CT, Scherzer R, Bacchetti P, et al. HIV viremia and changes in kidney function. AIDS. 2009;23:1089-1096.
21. Mauss S, Berger F, Kuschak D, et al. Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients. Antivir Ther. 2008;13:1091-1095.
22. Odden MC, Scherzer R, Bacchetti P, et al. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: The FRAM study. Arch Intern Med. 2007;167:2213-2219
23. Inker LA, Wyatt C, Creamer R, et al. Performance of cre-atinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals. J Acquir Immune Defi c Syndr. 2012;61(3):302-309.
24. Delanaye P, Mariat C, Cavalier E, Maillard N, Krzesinski JM, White CA. Trimethoprim, creatinine and creatinine-based equations. Nephron Clin Pract. 2011;119(3):187-193.
25. Atkins RC, Briganti EM, Zimmet PZ, Chadban SJ. Association between albuminuria and proteinuria in the general population: The AusDiab Study. Nephrol Dial Transplant. 2003;18(10):2170-2174.
26. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(Suppl):1-150.
27. Samarawickrama A, Cai M, Smith ER, et al. Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. HIV Med. 2012;13:526-532.
28. del Palacio M, Romero S, Casado JL. The use of bio-markers for assessing HAART-associated renal toxicity in HIV-infected patients. Curr HIV Res. 2012;10(6):521-531.
29. Imel EA, Econs MJ. Approach to the hypophosphatemic patient. J Clin Endocrinol Metab. 2012;97(3):696-706.
30. Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir neph-rotoxicity: Acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78(11):1171-7.
31. Taiwo B, Yanik EL, Napravnik S, et al. Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy. AIDS. 2013;27(10):1593-1602.
32. Imamura Y, Murayama N, Okudaira N et al. Prediction of fluoroquinolone-induced elevation in serum creatinine levels: A case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther. 2011;89(1):81-88.